Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.

TitleCirculating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Publication TypeJournal Article
Year of Publication2021
AuthorsConteduca V, Ku S-Y, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JMiguel, Schonhoft JD, Beltran H
JournalNPJ Precis Oncol
Volume5
Issue1
Pagination76
Date Published2021 Aug 12
ISSN2397-768X
Abstract

Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer.

DOI10.1038/s41698-021-00211-1
Alternate JournalNPJ Precis Oncol
PubMed ID34385567
PubMed Central IDPMC8361159
Grant ListW81XWH-17-1-0653 / / U.S. Department of Defense (United States Department of Defense) /
R27CA241486 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
P50 CA211024 / CA / NCI NIH HHS / United States
P50-CA211024 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
R37 CA241486 / CA / NCI NIH HHS / United States